ZyVersa Therapeutics Inc. Email Format

Pharmaceutical ManufacturingFlorida, United States11-50 Employees

ZyVersa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for renal and inflammatory diseases. Its lead renal program, VAR 200, targets the removal of excess intracellular lipids within the kidney’s filtration system, with the aim of mitigating kidney damage that can lead to end-stage kidney disease. The lead anti-inflammatory candidate, IC 100, acts as an inflammasome ASC inhibitor intended to block the initiation and progression of inflammation across a range of inflammatory conditions.
Headquartered in Weston, Florida, ZyVersa operates within the pharmaceutical manufacturing sector and pursues development programs through two licensed proprietary platforms. The company positions itself to address unmet medical needs in its chosen therapeutic areas, pursuing clinical-stage development and collaboration opportunities as part of its strategy. Recent updates highlight ongoing efforts to advance VAR 200 and IC 100, with public communications noting progress in these programs.

Get verified ZyVersa Therapeutics Inc. emails free

Company overview Employee directory